vs
Side-by-side financial comparison of ABERCROMBIE & FITCH CO (ANF) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.3B, roughly 1.8× ABERCROMBIE & FITCH CO). Zoetis runs the higher net margin — 25.3% vs 8.8%, a 16.5% gap on every dollar of revenue. On growth, ABERCROMBIE & FITCH CO posted the faster year-over-year revenue change (6.8% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $131.8M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -5.8%).
Abercrombie & Fitch Co. (A&F) is an American lifestyle retailer founded in 1892, which focuses on contemporary clothing targeting customers in their early 20s to mid 40s. Headquartered in New Albany, Ohio, the company operates four offshoot brands: Abercrombie Kids, Your Personal Best, Hollister Co., and Gilly Hicks with 780+ company operated stores across its brands, as of Q4 2024.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
ANF vs ZTS — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $2.4B |
| Net Profit | $113.0M | $603.0M |
| Gross Margin | 62.5% | 70.2% |
| Operating Margin | 12.0% | 31.9% |
| Net Margin | 8.8% | 25.3% |
| Revenue YoY | 6.8% | 3.0% |
| Net Profit YoY | -14.4% | 3.8% |
| EPS (diluted) | $2.36 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | $2.4B | ||
| Q3 25 | $1.2B | $2.4B | ||
| Q2 25 | $1.1B | $2.5B | ||
| Q1 25 | $1.6B | $2.2B | ||
| Q4 24 | $1.2B | $2.3B | ||
| Q3 24 | $1.1B | $2.4B | ||
| Q2 24 | $1.0B | $2.4B | ||
| Q1 24 | $1.5B | $2.2B |
| Q4 25 | $113.0M | $603.0M | ||
| Q3 25 | $141.4M | $721.0M | ||
| Q2 25 | $80.4M | $718.0M | ||
| Q1 25 | $187.2M | $631.0M | ||
| Q4 24 | $132.0M | $581.0M | ||
| Q3 24 | $133.2M | $682.0M | ||
| Q2 24 | $113.8M | $624.0M | ||
| Q1 24 | $158.4M | $599.0M |
| Q4 25 | 62.5% | 70.2% | ||
| Q3 25 | 62.6% | 71.5% | ||
| Q2 25 | 62.0% | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | 65.1% | 69.5% | ||
| Q3 24 | 64.9% | 70.6% | ||
| Q2 24 | 66.4% | 71.7% | ||
| Q1 24 | 62.9% | 70.6% |
| Q4 25 | 12.0% | 31.9% | ||
| Q3 25 | 17.1% | 37.0% | ||
| Q2 25 | 9.3% | 36.7% | ||
| Q1 25 | 16.2% | 36.5% | ||
| Q4 24 | 14.8% | 31.6% | ||
| Q3 24 | 15.5% | 36.6% | ||
| Q2 24 | 12.7% | 33.0% | ||
| Q1 24 | 15.3% | 34.1% |
| Q4 25 | 8.8% | 25.3% | ||
| Q3 25 | 11.7% | 30.0% | ||
| Q2 25 | 7.3% | 29.2% | ||
| Q1 25 | 11.8% | 28.4% | ||
| Q4 24 | 10.9% | 25.1% | ||
| Q3 24 | 11.7% | 28.6% | ||
| Q2 24 | 11.2% | 26.4% | ||
| Q1 24 | 10.9% | 27.4% |
| Q4 25 | $2.36 | $1.37 | ||
| Q3 25 | $2.91 | $1.63 | ||
| Q2 25 | $1.59 | $1.61 | ||
| Q1 25 | $3.55 | $1.41 | ||
| Q4 24 | $2.50 | $1.29 | ||
| Q3 24 | $2.50 | $1.50 | ||
| Q2 24 | $2.14 | $1.37 | ||
| Q1 24 | $2.97 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $631.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $3.3B |
| Total Assets | $3.5B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $631.0M | — | ||
| Q3 25 | $603.5M | $2.1B | ||
| Q2 25 | $607.6M | $1.4B | ||
| Q1 25 | $888.9M | $1.7B | ||
| Q4 24 | $738.9M | $2.0B | ||
| Q3 24 | $738.4M | $1.7B | ||
| Q2 24 | $864.2M | $1.6B | ||
| Q1 24 | $900.9M | $2.0B |
| Q4 25 | $1.3B | $3.3B | ||
| Q3 25 | $1.3B | $5.4B | ||
| Q2 25 | $1.2B | $5.0B | ||
| Q1 25 | $1.3B | $4.7B | ||
| Q4 24 | $1.2B | $4.8B | ||
| Q3 24 | $1.2B | $5.2B | ||
| Q2 24 | $1.1B | $5.0B | ||
| Q1 24 | $1.0B | $5.1B |
| Q4 25 | $3.5B | $15.5B | ||
| Q3 25 | $3.3B | $15.2B | ||
| Q2 25 | $3.1B | $14.5B | ||
| Q1 25 | $3.3B | $14.1B | ||
| Q4 24 | $3.3B | $14.2B | ||
| Q3 24 | $3.0B | $14.4B | ||
| Q2 24 | $3.0B | $14.2B | ||
| Q1 24 | $3.0B | $14.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $200.1M | $893.0M |
| Free Cash FlowOCF − Capex | $131.8M | $732.0M |
| FCF MarginFCF / Revenue | 10.2% | 30.7% |
| Capex IntensityCapex / Revenue | 5.3% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.77× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $384.5M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $200.1M | $893.0M | ||
| Q3 25 | $116.9M | $938.0M | ||
| Q2 25 | $-4.0M | $486.0M | ||
| Q1 25 | $307.6M | $587.0M | ||
| Q4 24 | $142.6M | $905.0M | ||
| Q3 24 | $165.1M | $951.0M | ||
| Q2 24 | $95.0M | $502.0M | ||
| Q1 24 | $303.3M | $595.0M |
| Q4 25 | $131.8M | $732.0M | ||
| Q3 25 | $50.7M | $805.0M | ||
| Q2 25 | $-54.8M | $308.0M | ||
| Q1 25 | $256.8M | $438.0M | ||
| Q4 24 | $92.2M | $689.0M | ||
| Q3 24 | $122.3M | $784.0M | ||
| Q2 24 | $56.1M | $370.0M | ||
| Q1 24 | $274.1M | $455.0M |
| Q4 25 | 10.2% | 30.7% | ||
| Q3 25 | 4.2% | 33.5% | ||
| Q2 25 | -5.0% | 12.5% | ||
| Q1 25 | 16.2% | 19.7% | ||
| Q4 24 | 7.6% | 29.7% | ||
| Q3 24 | 10.8% | 32.8% | ||
| Q2 24 | 5.5% | 15.7% | ||
| Q1 24 | 18.9% | 20.8% |
| Q4 25 | 5.3% | 6.7% | ||
| Q3 25 | 5.5% | 5.5% | ||
| Q2 25 | 4.6% | 7.2% | ||
| Q1 25 | 3.2% | 6.7% | ||
| Q4 24 | 4.2% | 9.3% | ||
| Q3 24 | 3.8% | 7.0% | ||
| Q2 24 | 3.8% | 5.6% | ||
| Q1 24 | 2.0% | 6.4% |
| Q4 25 | 1.77× | 1.48× | ||
| Q3 25 | 0.83× | 1.30× | ||
| Q2 25 | -0.05× | 0.68× | ||
| Q1 25 | 1.64× | 0.93× | ||
| Q4 24 | 1.08× | 1.56× | ||
| Q3 24 | 1.24× | 1.39× | ||
| Q2 24 | 0.83× | 0.80× | ||
| Q1 24 | 1.91× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANF
| Hollister | $673.3M | 52% |
| Abercrombie | $617.3M | 48% |
| Gift Card | $25.7M | 2% |
| Royalty | $19.5M | 2% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
